Canada markets closed

EyeGene Inc. (185490.KQ)

KOSDAQ - KOSDAQ Delayed Price. Currency in KRW
Add to watchlist
2,990.00+10.00 (+0.34%)
At close: 03:30PM KST

EyeGene Inc.

B-910, 401, Yangcheon-ro
Seoul 07528
South Korea
82 2 322 1687

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Won-Il YooChief Executive Officer and PresidentN/AN/AN/A
Dr. Yang-Je ChoCo-Founder and Chief Technology OfficerN/AN/AN/A
Soobeom LeeChief Financial OfficerN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.


EyeGene Inc., a biotechnology company, engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. The company's products in pipeline include EG-Mirotin, a Phase IIa clinical trial product candidate for the treatment of diabetic retinopathy; EG-Decorin, a Phase I/II clinical trial product for the treatment for pressure ulcers; EG-Myocin, a product that is in Phase II clinical trials for the treatment of heart muscle; and EG-HPV, a product that completed Phase I clinical trial for the treatment of cervical cancer. Its products in pipeline also include EG-TB for the treatment of tuberculosis; and EG-HZ, which is in preclinical trials for the treatment of herpes zoster. EyeGene Inc. was founded in 2000 and is headquartered in Seoul, South Korea.

Corporate Governance

EyeGene Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.